Diabetes Group — Reportable segment operating profit
Medtronic Diabetes Group — Reportable segment operating profit increased by 7.5% to $57.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 58.1%, from $136.00M to $57.00M. Over 4 years (FY 2021 to FY 2025), Diabetes Group — Reportable segment operating profit shows a downward trend with a -27.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates improved operational efficiency or higher margins, while a decrease suggests rising costs or pricing pressure.
Detailed definition
This measures the profitability of the diabetes segment after deducting operating expenses like R&D, SG&A, and productio...
Peer comparison
Standard operating profit metric for business segments in diversified corporations.
mdt_segment_diabetes_reportable_segment_operating_profitHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $113.00M | $133.00M | $157.00M | $161.00M | $13.00M | $77.00M | $96.00M | $106.00M | $80.00M | $84.00M | $101.00M | $118.00M | $100.00M | $102.00M | $116.00M | $136.00M | -$57.00M | $26.00M | $53.00M | $57.00M |
| QoQ Change | — | +17.7% | +18.0% | +2.5% | -91.9% | +492.3% | +24.7% | +10.4% | -24.5% | +5.0% | +20.2% | +16.8% | -15.3% | +2.0% | +13.7% | +17.2% | -141.9% | +145.6% | +103.8% | +7.5% |
| YoY Change | — | — | — | — | -88.5% | -42.1% | -38.9% | -34.2% | +515.4% | +9.1% | +5.2% | +11.3% | +25.0% | +21.4% | +14.9% | +15.3% | -157.0% | -74.5% | -54.3% | -58.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Medtronic's diabetes group — reportable segment operating profit?
- Medtronic (MDT) reported diabetes group — reportable segment operating profit of $57.00M in Q1 2026.
- How has Medtronic's diabetes group — reportable segment operating profit changed year-over-year?
- Medtronic's diabetes group — reportable segment operating profit decreased by 58.1% year-over-year, from $136.00M to $57.00M.
- What is the long-term trend for Medtronic's diabetes group — reportable segment operating profit?
- Over 4 years (2021 to 2025), Medtronic's diabetes group — reportable segment operating profit has grown at a -27.8% compound annual growth rate (CAGR), from $580.00M to $158.00M.
- What does diabetes group — reportable segment operating profit mean?
- The profit earned by the diabetes segment from its core operations before corporate overhead and taxes.